COMMUNIQUÉS West-GlobeNewswire

Aveanna Healthcare Announces Successful Debt Refinancing
18/09/2025
ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (Nasdaq: AVAH) today announced the closing of its refinanced first lien credit facility. The refinanced credit facility provides [...]
Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory
18/09/2025
Certification critical to broad U.S. market release of the CNSide CSF Assay Platform CNSide now meets key federal and state regulatory requirements, including those set by the Centers for Medicare and Medicaid Services [...]
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema
18/09/2025
Completed patient enrollment within nine months with nearly half enrolled from the U.S. Expect to report Phase 3 topline data in the first half of 2026 On track to submit BLA in the second half of 2026 for an [...]
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025
18/09/2025
Long-Term Data from FOREST-HCM in Non-Obstructive HCM and Results from Prespecified Analysis of MAPLE-HCM to be Presented in Late-Breaking Clinical Research Session SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE [...]
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
18/09/2025
Regulatory Milestone Underscores Continued Promise of First-in-Class Mitochondrial Cell Therapy HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage [...]
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
18/09/2025
Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD) Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc [...]
Cullgen Completes Enrollment in Phase 1 Trial of its Novel Non-Opioid Pain Product Candidate CG001419
18/09/2025
- Cullgen anticipates filing an IND and starting phase 2 clinical trials in early 2026 for this candidate which is part of a new class of pain signaling channel modulators - SAN DIEGO, Sept. 18, 2025 (GLOBE NEWSWIRE [...]
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
18/09/2025
NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today [...]
Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
18/09/2025
- Results were published in JACC: Basic to Translational Science - - Publication evaluated coronary tissue engineered vessel (CTEV) as a conduit for CABG in a nonhuman primate model - - All implanted CTEVs remained [...]
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up
18/09/2025
SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the [...]
KFSHRC to Participate in C3 Davos of Healthcare™ Japan Summit
18/09/2025
TOKYO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) has announced its participation in the C3 Davos of Healthcare™ Japan Summit, taking place on September 24, 2025 [...]
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland
18/09/2025
STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study
18/09/2025
Ozempic ® (once-weekly injectable semaglutide) was associated with a 23% reduced risk of heart attack, stroke and death in people with type 2 diabetes and cardiovascular disease on Medicare versus dulaglutide 1 Data [...]
Epitopea Strengthens Scientific Advisory Board with Appointment of Four World Renowned Experts in Cancer Immunology and Immunotherapy
18/09/2025
CAMBRIDGE, United Kingdom and MONTREAL, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the [...]
Epitopea renforce son comité consultatif scientifique avec la nomination de quatre experts de renommée mondiale en immunologie et immunothérapie du cancer
18/09/2025
CAMBRIDGE, ROYAUME-UNI et MONTRÉAL, 18 sept. 2025 (GLOBE NEWSWIRE) -- Epitopea, une société transatlantique spécialisée dans l'immunothérapie anticancéreuse qui développe des immunothérapies accessibles et prêtes à l' [...]
Imprivata, éditeur international de solutions de gestion des accès, se développe sur le marché français pour répondre à la demande croissante en matière de sécurité et de conformité
18/09/2025
Initialement axées sur les soins de santé, les solutions Imprivata permettent un accès clinique rapide et sécurisé aux services informatiques afin de soutenir le programme CaRE et en particulier le domaine HospiConnect [...]
Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy
18/09/2025
Detailed results from clinical feasibility studies show immediate improvement in blood pressure stability and durable reduction of hypotensive symptoms, resulting in improved quality of life Most people living with [...]
89bio, Inc. Announces Agreement to be Acquired by Roche
18/09/2025
– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash [...]
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
18/09/2025
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most prevalent comorbidities of obesity Acquisition [...]

Pages